

## DCVMN Workshop Exercise 2

Underlined/red words are directions or notes for completing this exercise. In this scenario, you are the author.

This is not a test. This is an exercise to get people thinking and discussing their approaches to Assay Validation.

**Validation Plan (This document is based on NIBSC's approach to assay validation)**

**Indicate here the analytical procedure that you are validating**

Title	
Document Reference	
Division/Study Area	

### Document Approval

**For items 1, 2 & 3, list who else in the quality management chain should approve this Validation Plan**

Author			
Name	Position	Signature	Date
<b>1</b>			
Name	Position	Signature	Date
<b>2</b>			
Name	Position	Signature	Date
<b>3</b>			
Name	Position	Signature	Date

### Contents

1. Introduction .....	2
2. Scope .....	2

---

3. Validation Plan .....	3
3.1 Validation Approach .....	3
3.2 Validation Parameters .....	3
3.3 Format of Validation Exercise .....	4
3.4 Validation Criteria .....	4
4. Procedure .....	5
5. Impact of Validation .....	6
Appendix A .....	6

## 1. Introduction

*Provide an outline and context for the validation i.e. what is being validated and why.*

## 2. Scope

*Describe the method to be validated including details of the products / samples to which it is applied, summary of the assay / test performed along with details of the equipment and software used.*

*Note:*

- *for new methods state whether it is replacing another method and summarise any method development work*
- *for modifications to existing methods describe the modifications being made the reasoning behind making the changes and the impact of the modifications on the performance of the method*

*Include references to SOPs, published papers, monographs, investigation reports, previous validation work.*

## 3. Validation Plan

### 3.1 Validation Approach

Provide rationale for the validation approach to be taken based on the method to be validated e.g.

- Pharmacopoeial (compendial method)
- Validated/approved method of a manufacturer or other laboratory
- Non compendial published method
- Method of a first manufacturer to be used for a product of a second manufacturer
- Method for an active substance to be used for a medicinal product
- Methods to reduce, refine or replace animal use (3Rs)
- New in-house procedure

Refer to PA/PH/OMCL (13) 82 2R for further guidance

### 3.2 Validation Parameters

Provide details of parameters which will be tested during the validation exercise e.g.

- Accuracy
- Precision
  - o Repeatability
  - o Intermediate Precision
- Specificity
- Detection Limit
- Quantitation Limit
- Linearity
- Range

Refer to ICH Guideline Q2(R1) for further guidance

### 3.3 Format of Validation Procedure

Describe the design of the validation exercise e.g.

- Type of samples to be tested, whether previous results are available from a previously validated method
- How many samples / plates / assays to be tested
- How many replicates will be included
- Whether multiple operators will carry out the testing
- What controls and reference samples will be included
- What critical equipment will be utilised
- Which software packages will be utilised

Include a summary table if useful:

<b>Samples to be tested (e.g. number and type)</b>	<b>Source of samples</b>	<b>Parameter to be tested</b>

### 3.4 Validation Criteria

Describe the criteria which must be met for the validation to be deemed successful.

If less than 100% performance is acceptable specify what level of performance is acceptable plus some justification.

In some cases it may not possible to define specific acceptance criteria, instead how a system performs may be sufficient measure, if this is the case describe what validation success would look like so that a conclusion can be drawn on the outcome of the validation exercise.

Include a summary table if useful

e.g.

<b><u>Test Parameter</u></b>	<b><u>Acceptance Criteria</u></b>	<b><u>Specification</u></b>
<u>e.g. Accuracy</u>	<u>e.g. 100% of validation data points to fall within XYZ</u>	<u>e.g. PhEur N.N.N method X</u>

Validation Criteria continued

Test Parameter	Acceptance Criteria	Specification

## 4. Procedure

*Describe the procedure to be followed for the validation exercise, either reference SOP highlighting any deviations from the procedure documented in the SOP or provide step by step instructions here.*

*e.g.*

<b>Step</b>	<b>Action</b>
<u>1</u>	<i>e.g. Prepare 10 samples for assay Y using sample preparation method Z, refer to SOP s/n XXXX</i>
<u>2</u>	<i>e.g. Run 2 plates using instrument protocol ABC as described in steps 10 to 18 of SOP s/n XXXX</i>
<u>3</u>	<i>e.g. Transfer raw data to form s/n XXXX and perform statistically analysis</i>

<b>Step</b>	<b>Action</b>
1	
2	
3	
4	
5	
6	Etc.

## 5. Impact of Validation

Document your assessment of the impact of the validation exercise:

- what documents will need revising e.g. SOPs, forms, study plans
- what records need creating or updating e.g. equipment records, training records, critical reagents list
- how will staff be trained to the new / modified method and ongoing competency assessed
- how will the performance of the method be monitored
- how will the uncertainty of measurement been accessed and documented
- what LIMS changes are required

## Appendix A

Appendices can be added and deleted as required to include details of items referred to in the body of the validation plan e.g. specifications of reagents / equipment, flow diagrams.

Or appendices can be added to contain results tables to be populated during the validation exercise.

Sample ID	Test parameter	Observed result	Acceptance criteria (Pass / Fail)
<u>e.g. 123456</u>	<u>e.g. Accuracy</u>	<u>e.g. 2.2 RPU</u>	<u>e.g. Pass</u>
etc			

Who in the quality management chain should complete and check this Validation Plan prior to authorisation?

<b><u>Completed by</u></b>			
Name	Position	Signature	Date

  

<b><u>Checked by</u></b>			
Name	Position	Signature	Date

## **Postscript**

*This exercise is based on NIBSC's approach to assay validation planning in its role as a National Control Laboratory. NIBSC does not manufacture biological medicines and so does not operate under a GMP quality management system. List below any additional items that a Manufacturer's QC laboratory would document when writing a Validation Plan for this assay.*